Clinical Trials Logo

Clinical Trial Summary

We seek to refine and evaluate the novel mobile intervention, Mobile Anxiety Sensitivity Program for Smoking (MASP) which was initially developed and previously tested by our team, targeting sensitivity to interoceptive stress, and to apply it among African American smokers. Our culturally adapted intervention is framed within a sociocultural context of interoceptive stress, which is supported by theory, empirical evidence, and characteristics of African American smokers. The MASP app contains educational content on the history of tobacco and the African American community.


Clinical Trial Description

The objective of the current trial is to refine and conduct a comprehensive cultural adaptation of an initially tested novel, mobile intervention that targets anxiety sensitivity (AS) among African American smokers (MASP). The MASP app checks in with users throughout the day to assess their mood, whether or not they're experiencing any cravings or withdrawal symptoms, and their overall mental health. When users indicate they are struggling with staying abstinent, or if they are experiencing heighted levels of stress or anxiety, the app selects and delivers a tailored message from its library of hundreds of messages and videos. For instance, if a user indicates they are struggling with nicotine cravings, and feel as though they are about to smoke, they will receive an individually tailored suggestion on how to cope with the feeling, and strategies to act and overcome it. The app also contains videos that are designed to teach relaxation techniques, as well as training exercises that teach participants how to cope with uncomfortable feelings of stress and nicotine withdrawal they are likely to experience while quitting nicotine. The MASP app has the potential to deliver highly effective and accessible treatment to individuals who are looking to take that major step in their life, and quit smoking for good. Individuals interested in participating in the study will complete informed consent and a study screener via RedCap and phone call with study staff (signatures will be obtained digitally via RedCap). Those found eligible during the phone screener will download the Insight app onto their personal phone to confirm compatibility and complete the baseline assessment. Those who do not possess a phone that is compatible with the Insight platform will be mailed a compatible phone so they can complete the baseline assessment. Upon completion of the baseline survey, participants will be mailed a Bedfont Carbon Monoxide monitor (iCO) that can be used to remotely verify smoking status, a Greenphire Mastercard, and 4 weeks of NRT. Upon receipt of the iCO, participants will complete a brief phone call to walk them through the use of the iCO and study app. Participants (N=25) in phase II will be in the study for a total of 6 weeks. Upon completion of Phase II, we will analyze data and utilize feedback collected from phase II participants to create MASP 3.0. We will then begin phase III of the study. Participants (N=220) in the study will receive either the MASP 3.0 or QuitGuide plus EMA app following the completion of the baseline assessment. Specifically, following completion on the baseline assessment they will receive a unique code that they will type into the app to place them in the group that they were randomized to. All participants will complete app-based follow-up assessments 1, 2 (quit day), 3, 4, 5, 6, 28, and 54 weeks after the baseline visit. We expect phase III of the study will be completed within a period of 30-36 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04838236
Study type Interventional
Source University of Houston
Contact Cameron Matoska, B.S.
Phone 713-743-8056
Email ctmatosk@central.uh.edu
Status Recruiting
Phase N/A
Start date December 20, 2021
Completion date March 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT04133064 - Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study N/A
Completed NCT06105424 - BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT03597607 - Evaluation of an Intensive Individualized Smoking Cessation Program Delivered by Pharmacists N/A
Completed NCT05960305 - CSD201204 An Actual Use Study of P12 Electronic Nicotine Delivery System Among U.S. Adult Smokers N/A
Terminated NCT03326128 - High Dose Bupropion for Smoking Cessation - Pilot Study Phase 2
Completed NCT04808609 - Smoking Cessation Pilot for People Living With HIV (PLWH) N/A
Completed NCT04310735 - Examining Brain Responses Linked to Emotion in Individuals Who Smoke Cigarettes N/A
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Enrolling by invitation NCT05554120 - The Next Step in Smoking Prevention: the Reduction of Tobacco Retail Outlets, a Comprehensive Policy Evaluation
Completed NCT03015597 - Pilot Study of Contingency Management for Smoking Cessation N/A
Completed NCT05506046 - Messages About Reduced Nicotine in Combusted Tobacco Products N/A
Active, not recruiting NCT04982952 - Contingency Management for Smoking Cessation N/A
Recruiting NCT05992272 - Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer
Completed NCT02428244 - Let's STOP Now Trial: Smoking in Trauma Orthopaedic Patients N/A
Recruiting NCT03962660 - Harm Reduction for Tobacco Smoking With Support of Tobacco-Replacing Electronic Nicotine Delivery Systems N/A
Completed NCT03200236 - The Lung Screening, Tobacco and Health Project Phase 3
Completed NCT04791722 - Optimizing Smoke-free Residential Housing Policies N/A
Completed NCT02968381 - A Guided Imagery Tobacco Cessation Intervention Delivered by a Quit Line and Website N/A
Completed NCT06456645 - Effects of Smoking on Placenta and Lactation